The potential economic value of a human norovirus vaccine for the United States.

@article{Bartsch2012ThePE,
  title={The potential economic value of a human norovirus vaccine for the United States.},
  author={Sarah M. Bartsch and Benjamin A Lopman and Aron J. Hall and Umesh Parashar and Bruce Y Lee},
  journal={Vaccine},
  year={2012},
  volume={30 49},
  pages={
          7097-104
        }
}
Vaccines against human norovirus are currently under development. We developed a simulation model to determine their potential economic value. Vaccination prevented 100-6125 norovirus gastroenteritis cases per 10,000 vaccinees. Low vaccine cost (≤$50) garnered cost-savings and a more expensive vaccine led to costs per case averted comparable to other vaccines. In the US, vaccination could avert approximately 1.0-2.2 million cases (efficacy 50%, 12 month duration), costing an additional $400… CONTINUE READING

Figures, Tables, and Topics from this paper.

Explore Further: Topics Discussed in This Paper

Citations

Publications citing this paper.
SHOWING 1-10 OF 37 CITATIONS

The state of norovirus vaccines.

  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2014
VIEW 9 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

References

Publications referenced by this paper.
SHOWING 1-10 OF 32 REFERENCES

Bureau

U. S. Censu
  • National Population Estimates.
  • 2010
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL

Increasing rates of gastroenteritis hospital discharges in US adults and the contribution of norovirus, 1996-2007.

  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2011
VIEW 1 EXCERPT